Comprehensive Tuberculosis Drug Resistance Analysis

Comprehensive Tuberculosis Drug Resistance Analysis – Genotypic & Phenotypic Profiling for Precision Management

You are searching for Mycobacterium tuberculosis drug resistance analysis because you need to perform this detection—whether to guide patient treatment, monitor resistance emergence in a clinical or epidemiological setting, screen for multidrug‑resistant (MDR) or extensively drug‑resistant (XDR) strains, or validate novel drug candidates against resistant isolates. We provide a complete resistance testing service that combines high‑throughput molecular genotyping, rapid phenotypic susceptibility testing, and whole‑genome sequencing (WGS) to deliver actionable resistance profiles with full clinical and public health interpretation.

What We Detect – Resistance Genes, Mutations & MIC Values for First‑ and Second‑Line Drugs

Our tuberculosis drug resistance analysis goes far beyond simple rifampicin (RIF) screening. Using a validated real‑time PCR panel (multiplex, 8 targets), we detect mutations in rpoB (RIF resistance), katG and inhA (isoniazid, INH), embB (ethambutol), pncA (pyrazinamide), gyrA/gyrB (fluoroquinolones), rrs and eis (aminoglycosides/capreomycin) – covering all first‑line and key second‑line drugs with sensitivity of 95‑99% for common mutations. For comprehensive profiling, we perform whole‑genome sequencing (WGS, Illumina, ≥100× coverage) of cultured isolates or smear‑positive clinical samples (with decontamination and host depletion), identifying all known resistance‑associated alleles across >40 genes including those for bedaquiline (Rv0678, atpE), delamanid (ddn, fgd1, fbiA‑C), clofazimine (Rv0678, pepQ), linezolid (rplC, rrl), and para‑aminosalicylic acid (thyA, folC). We also perform phenotypic drug susceptibility testing (DST) using the MGIT™ 960 system (BACTEC) for first‑ and second‑line drugs, reporting minimum inhibitory concentrations (MICs) in µg/mL with critical concentration interpretation following CLSI or WHO guidelines. For rapid turnaround directly from sputum or other respiratory specimens, we offer line probe assays (GenoType® MTBDRplus/sl) and Xpert® MTB/RIF Ultra – both with full internal controls and heteroresistance detection down to 5% mutant population.

How Deep We Go – Phylogenetic Lineage, Resistance Evolution & Transmission Clusters

We don't just report “resistant” or “susceptible”. Our advanced analysis includes full WGS‑based phylogenotyping to assign your isolate to M. tuberculosis lineage (L1‑L9, including Beijing, East‑African‑Indian, Euro‑American) – essential because lineage influences resistance acquisition rates and virulence. Using TB‑profiler or Mykrobe predictor combined with manual curation, we report specific allele (e.g., rpoB S450L, katG S315T, gyrA D94G) and predicted MIC shift (low vs. high level resistance). For heteroresistance (mixed wild‑type and mutant populations), our deep sequencing (≥500× coverage) detects minor variants as low as 2% frequency – critical for early resistance detection. We also perform whole‑genome SNP typing (≤12 SNP difference as cluster threshold) to identify transmission clusters in outbreak investigations, with minimum spanning trees and Bayesian phylogenetic reconstruction. For drug development support, we conduct resistance mechanism elucidation by mapping WGS data onto structural protein models (e.g., rpoB, gyrA, Ddn) to identify novel or compensatory mutations. Additionally, we offer functional validation of unknown mutations via mycobacteriophage‑based recombinase (phage‐phage) assays or CRISPRi knock‑in in BSL‑3 – confirming causality of new resistance alleles.

Why Our TB Resistance Analysis Stands Out – Rapid Turnaround, BSL‑3 Safe & Clinically Actionable Reporting

1. Full biosafety & speed: Our laboratory is BSL‑3 certified for live M. tuberculosis handling. For direct molecular testing from sputum (heat‑inactivated), we provide results in 24‑48 hours. For culture‑based MGIT DST, turnaround 7‑14 days. For WGS from isolate, 5‑7 business days (including assembly, annotation, resistance prediction).
2. Comprehensive drug coverage: We test 12 first‑/second‑line agents: RIF, INH, EMB, PZA, moxifloxacin, levofloxacin, amikacin, kanamycin, capreomycin, ethionamide, linezolid, bedaquiline, clofazimine. Custom panels for newer drugs (pretomanid, sutezolid) available.
3. High sensitivity for smear‑negative samples: Using targeted enrichment (SureSelect or Twist) for M. tuberculosis DNA directly from 1 mL sputum, we achieve WGS from samples with as few as 10 CFU/mL – avoiding culture delay.
4. Actionable clinical reporting: Our reports include drug‑by‑drug resistance calls (R, S, or intermediate), mutation significance (known, new, or silent), recommended regimen based on WHO guidelines, and lineage‑specific risk notes (e.g., Beijing lineage and high‑level INH resistance). For public health, we provide cluster IDs and outbreak investigation support.
5. Quality & accreditation: We participate in WHO supranational reference laboratory external quality assessment (EQA) for DST and WGS. Our methods follow CLSI M24, M48, and WHO Technical Report on TB resistance surveillance.

Who Relies on Our TB Drug Resistance Analysis – Real‑World Impact

A national TB reference laboratory sent us 100 MDR isolates with unknown second‑line resistance; our WGS identified gyrA mutations in 22 isolates (fluoroquinolone‑resistant) and rrs mutations in 8 (aminoglycoside‑resistant) – directly guiding XDR classification and treatment adjustments. A hospital infectious disease team used our rapid sputum PCR (24h) on a patient with treatment failure; we detected rpoB S531L and katG S315T (MDR) within 24 hours, enabling timely regimen change. A clinical trial of a novel drug candidate used our WGS and MGIT MIC testing to rule out pre‑existing resistance in 200 enrolled patients – supporting trial validity. An outbreak investigation in a homeless shelter relied on our phylogenetic clustering (≤5 SNP difference among 12 isolates) to confirm transmission, leading to targeted screening and reduced new cases.

Ready to Run Your Tuberculosis Drug Resistance Analysis?

Send us inactivated sputum (≥2 mL), bronchoalveolar lavage (≥5 mL), cultured isolate (on Löwenstein‑Jensen or MGIT, any amount), or extracted DNA (≥200 ng) – all shipped under Category B (UN3373) or A (UN2814) as appropriate. We will perform rapid molecular screening (Xpert/line probe), full WGS with resistance prediction, or phenotypic MGIT DST according to your needs. Request a free consultation; we will design the optimal analysis pathway (screening, confirmatory, outbreak typing, or clinical guidance) for your patient, public health, or research context.